Scienmag

MARCH 3, 2021

Results could lead to better drugs used to fight inflammation At the beginning of an immune response, a molecule known to mobilize immune cells into the bloodstream, where they home in on infection sites, rapidly shifts position, a new study shows.

Immune Response 57

Immune Response Drugs Research Dermatology 57

The Pharma Data

JUNE 19, 2022

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, they can wear out and cease to function. In addition, the researchers found that the drug combination was not toxic to the animals.

Drugs 52

Drugs Protein Immune Response Dermatology 52

The Pharma Data

OCTOBER 9, 2021

Ulcerative colitis (UC), a chronic inflammatory bowel disease (IBD), is characterized by an irregular, chronic immune response that creates inflammation and ulcers (sores) in the mucosa (lining) of the large intestine (colon) or rectum. Deucravacitinib is not approved for use in any country. About Ulcerative Colitis.

Trials 52

Trials Immune Response Dermatology Clinical Trials 52

The Pharma Data

APRIL 28, 2021

These and other data from real-world settings and clinical trials, including the Dupixent open-label extension (OLE) trials, will be presented at the American Academy of Dermatology (AAD VMX 2021), April 23-25, and at the 20 th European Society for Pediatric Dermatology Annual Meeting (ESPD 2021), May 12-14.

Dermatology 40

Dermatology Trials Clinical Trials Clinical Trials 40

The Pharma Data

APRIL 4, 2023

Immune-mediated adverse reactions, which may be severe or fatal, can occur in any organ system or tissue and can affect more than one body system simultaneously. Important immune-mediated adverse reactions listed here may not include all possible severe and fatal immune-mediated adverse reactions.

FDA Approval 40

FDA Approval Containment Hormones Dermatology 40

The Pharma Data

MARCH 16, 2021

These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021. Vice President, Rheumatology Disease Area Leader, Janssen Research & Development, LLC. 1,2 TREMFYA is the first and only IL-23 inhibitor therapy approved in the U.S.

Medicine 52

Medicine Doctors Doctor Development 52

The Pharma Data

SEPTEMBER 15, 2020

I am proud of the truly transformational science that our research and clinical teams are bringing to the fight against disease, as well as the unprecedented speed with which we are advancing our clinical programs in the battle against COVID-19. Internal Medicine. THERAPEUTIC AREAS OF FOCUS. Inflammation and Immunology.

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52